Literature DB >> 16416025

Clostridial neurotoxins: structure-function led design of new therapeutics.

J A Chaddock1, P M H Marks.   

Abstract

The neurotoxins produced by various species of Clostridia are the causative agents of botulism and tetanus. The ability of the toxins, specifically those of the botulinum neurotoxin family, to disrupt neurotransmission has been exploited for use in several medical indications and now represents the therapeutic option of choice in a number of cases. Clostridial neurotoxins have been discovered to have a multi-domain structure that is shared between the various proteins of the family, and it has also been determined that each domain contributes a specific role to the holotoxin. The extensive use of recombinant expression approaches, along with solution of multiple crystallographic structures of individual domains, has enabled researchers to explore structurefunction relationships of the toxin domains more closely. These advances have facilitated a greater understanding of the potential use of individual domains for a wide variety of purposes, including the development of new therapeutics.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16416025     DOI: 10.1007/s00018-005-5505-5

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  9 in total

1.  Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1.

Authors:  Christina L Pier; Chen Chen; William H Tepp; Guangyun Lin; Kim D Janda; Joseph T Barbieri; Sabine Pellett; Eric A Johnson
Journal:  FEBS Lett       Date:  2010-11-30       Impact factor: 4.124

2.  Sensitive and quantitative detection of botulinum neurotoxin in neurons derived from mouse embryonic stem cells.

Authors:  Sabine Pellett; Zhong-wei Du; Christina L Pier; William H Tepp; Su-chun Zhang; Eric A Johnson
Journal:  Biochem Biophys Res Commun       Date:  2010-12-03       Impact factor: 3.575

Review 3.  Targeted secretion inhibitors-innovative protein therapeutics.

Authors:  Foster Keith; Chaddock John
Journal:  Toxins (Basel)       Date:  2010-12-03       Impact factor: 4.546

Review 4.  Towards new uses of botulinum toxin as a novel therapeutic tool.

Authors:  Andy Pickett; Karen Perrow
Journal:  Toxins (Basel)       Date:  2011-01-12       Impact factor: 4.546

5.  Analysis of gene expression in induced pluripotent stem cell-derived human neurons exposed to botulinum neurotoxin A subtype 1 and a type A atoxic derivative.

Authors:  Jacob M Scherf; Xiaoyang Serene Hu; William H Tepp; Konstantin Ichtchenko; Eric A Johnson; Sabine Pellett
Journal:  PLoS One       Date:  2014-10-22       Impact factor: 3.240

6.  A Cell Line for Detection of Botulinum Neurotoxin Type B.

Authors:  Aleksander Rust; Ciara Doran; Rosalyn Hart; Thomas Binz; Paul Stickings; Dorothea Sesardic; Andrew A Peden; Bazbek Davletov
Journal:  Front Pharmacol       Date:  2017-11-09       Impact factor: 5.810

7.  Stapling of the botulinum type A protease to growth factors and neuropeptides allows selective targeting of neuroendocrine cells.

Authors:  Jason Arsenault; Enrico Ferrari; Dhevahi Niranjan; Sabine A G Cuijpers; Chunjing Gu; Yvonne Vallis; John O'Brien; Bazbek Davletov
Journal:  J Neurochem       Date:  2013-05-20       Impact factor: 5.372

8.  Production and characterization of recombinant light chain and carboxyterminal heavy chain fragments of tetanus toxin.

Authors:  Mehdi Yousefi; Roya Khosravi-Eghbal; Azam Hemmati; Fazel Shokri
Journal:  Avicenna J Med Biotechnol       Date:  2013-10

9.  Botulinum protease-cleaved SNARE fragments induce cytotoxicity in neuroblastoma cells.

Authors:  Jason Arsenault; Sabine A G Cuijpers; Enrico Ferrari; Dhevahi Niranjan; Aleksander Rust; Charlotte Leese; John A O'Brien; Thomas Binz; Bazbek Davletov
Journal:  J Neurochem       Date:  2014-01-23       Impact factor: 5.372

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.